Ep. 79 - BNP Paribas’ Moneer on Biotech’s Bull Case: M&A, PE, and Market Recovery
From The BioCentury Show · · 29 min
This plays from the publisher's own server. We do not host a copy.
Description
Since the annual J.P. Morgan Healthcare Conference in San Francisco in early January, biotech has seen a notable surge in enthusiasm, Zahid Moneer, senior managing director of investment banking at BNP Paribas, told The BioCentury Show. Moneer, who is more upbeat than many in today’s biopharma sector, sees capital raises from million-dollar seed rounds to nine-digit series A, B, and C rounds driving significant growth alongside M&A activity. In the interview, he also also highlights the growing role of private equity firms in biopharma and the trend of pharmas engaging earlier with biotechs and investors looking to deploy capital into those companies
View full story: https://www.biocentury.com/article/655216
#biotech #biopharma #pharma #lifescience #financing #privateequity #IPO
00:00 - Introduction 00:37 - Investment Climate 05:06 - Pharma M&A Activity 15:25 - Private Equity's Role 21:44 - Biotech Financing